PDGFRβ and oncogenic mutant PDGFRα D842V promote disassembly of primary cilia through a PLCγ- and AURKA-dependent mechanism.

J Cell Sci

Department of Biology, Section of Cell and Developmental Biology, The August Krogh Building, University of Copenhagen, Universitetsparken 13, Copenhagen OE DK-2100, Denmark

Published: October 2015

Primary cilia are microtubule-based sensory organelles projecting from most quiescent mammalian cells, which disassemble in cells cultured in serum-deprived conditions upon re-addition of serum or growth factors. Platelet-derived growth factors (PDGF) are implicated in deciliation, but the specific receptor isoforms and mechanisms involved are unclear. We report that PDGFRβ promotes deciliation in cultured cells and provide evidence implicating PLCγ and intracellular Ca(2+) release in this process. Activation of wild-type PDGFRα alone did not elicit deciliation. However, expression of constitutively active PDGFRα D842V mutant receptor, which potently activates PLCγ (also known as PLCG1), caused significant deciliation, and this phenotype was rescued by inhibiting PDGFRα D842V kinase activity or AURKA. We propose that PDGFRβ and PDGFRα D842V promote deciliation through PLCγ-mediated Ca(2+) release from intracellular stores, causing activation of calmodulin and AURKA-triggered deciliation.

Download full-text PDF

Source
http://dx.doi.org/10.1242/jcs.173559DOI Listing

Publication Analysis

Top Keywords

pdgfrα d842v
16
d842v promote
8
primary cilia
8
growth factors
8
ca2+ release
8
deciliation
6
pdgfrα
5
pdgfrβ oncogenic
4
oncogenic mutant
4
mutant pdgfrα
4

Similar Publications

Identification of D842V mutation in gastrointestinal stromal tumors based on CT radiomics: a multi-center study.

Cancer Imaging

December 2024

Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Pujian Road 160, Pudong District, 200127, Shanghai, China.

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Recent advent of tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis of GIST patients. However, responses to TKI therapy can vary depending on the specific gene mutation.

View Article and Find Full Text PDF
Article Synopsis
  • * Avapritinib, a tyrosine kinase inhibitor approved for certain gastrointestinal tumors, showed a partial response in a case study of a 55-year-old man with a D842V-mutant gastrointestinal stromal tumor (GIST) associated with a sporadic desmoid tumor.
  • * This case highlights avapritinib's potential effectiveness against desmoid tumors, warranting further investigation in controlled clinical trials due to the limited existing treatment options.
View Article and Find Full Text PDF

Tissue biopsy remains the standard for diagnosing gastrointestinal stromal tumors (GISTs), although liquid biopsy is emerging as a promising alternative in oncology. In this pilot study, we advocate for droplet digital PCR (ddPCR) to diagnose GIST in tissue samples and explore its potential for early diagnosis via liquid biopsy, focusing on the D842V mutation and hypermethylated gene. We utilized ddPCR to analyze the predominant mutation (D842V) in surgical tissue samples from 15 GIST patients, correlating with pathologists' diagnoses.

View Article and Find Full Text PDF

Background: Incidentally found masses are a widely discussed area of medicine, and there are conflicting opinions as to how to deal with these findings, particularly in the stomach-which has limited documentation in the literature. Here we present a middle-aged female who was found to have an incidentally found mass on her remnant stomach 10 years after a Roux-en-Y gastric bypass (RYGB) surgery.

Case Presentation: We present the case of a 66-year-old female who is 10 years post-op from a RYGB.

View Article and Find Full Text PDF

Background: Gastrointestinal stromal tumor (GIST) is a rare mesenchymal tumor arising in the gut, most commonly stomach or small bowel. The most common driver mutations are and which can be treated with imatinib or avapritinib (for PDGFRA D842V-mutant GIST), respectively. V600E mutant GISTs are rare and these do not respond to imatinib.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!